Determining Optimal Free Dose Combination of Tiotropium Bromide and BI 1744 CL in Chronic Obstructive Pulmonary Disease (COPD)

NCT01040403 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

233

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG: olodaterol (BI 1744) low
DRUG: low tiotropium bromide
DRUG: olodaterol (BI 1744) high
DRUG: medium tiotropium bromide
DRUG: high tiotropium bromide
DRUG: Placebo
DEVICE: Respimat

Sponsor

Boehringer Ingelheim